Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 4/20 | 0.61 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.61 |
| ▸ | MELK | Q14680 | 1/20 | 0.61 |
| ▸ | STK24 | Q9Y6E0 | 1/20 | 0.61 |
| ▸ | PARP1 | P09874 | 8/20 | 0.49 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | DAO | P14920 | 1/20 | 0.40 |
| ▸ | DDO | Q99489 | 1/20 | 0.40 |
| ▸ | JAK3 | P52333 | 1/20 | 0.36 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28399234 | 0.83 | JAK2 (0.45) | JAK2RPS6KA3MELKSTK24PARP1 | |
| SCHEMBL168637 | 0.80 | JAK2 (0.61) | JAK2RPS6KA3MELKSTK24PARP1 | |
| SCHEMBL30223152 | 0.76 | CHEK1 (0.51) | JAK2RPS6KA3MELKSTK24PARP1 | |
| SCHEMBL11775264 | 0.76 | JAK2 (0.61) | JAK2RPS6KA3MELKSTK24PARP1 | |
| SCHEMBL27851304 | 0.76 | JAK2 (0.39) | JAK2RPS6KA3MELKSTK24PARP1 | |
| SCHEMBL3117561 | 0.76 | JAK2 (0.61) | JAK2RPS6KA3MELKSTK24PARP1 | |
| SCHEMBL3934745 | 0.76 | JAK2 (1.00) | JAK2RPS6KA3MELKSTK24PARP1 | |
| SCHEMBL22093860 | 0.76 | JAK2 (0.44) | JAK2RPS6KA3MELKSTK24PARP1 | |
| SCHEMBL22094664 | 0.76 | CHEK1 (0.51) | JAK2RPS6KA3MELKSTK24PARP1 | |
| SCHEMBL19687778 | 0.76 | JAK2 (0.56) | JAK2RPS6KA3MELKSTK24PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113923988-B | Substituted arylmethyl ureas and heteroarylmethyl ureas, analogs thereof, and methods of using the same | 爱彼特生物制药公司 | 2024-12-13 | — | — | CN | disclosed |
| EP-3893645-B1 | SUBSTITUTED ARYLMETHYLUREAS AND HETEROARYLMETHYLUREAS, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORP (CA) | 2024-04-17 | — | — | EP | disclosed |
| EP-4330246-A1 | HALO-SUBSTITUTED AMINO AZA-HETEROARYL COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) | Ontario Institute for Cancer Research (OICR) (CA) | 2024-03-06 | — | — | EP | disclosed |
| US-20230045421-A1 | SUBSTITUTED ARYLMETHYLUREAS AND HETEROARYLMETHYLUREAS, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORP (CA) | 2023-02-09 | — | — | US | disclosed |
| US-20230045421-A1 | SUBSTITUTED ARYLMETHYLUREAS AND HETEROARYLMETHYLUREAS, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORP (CA) | 2023-02-09 | — | — | US | disclosed |
| WO-2022226665-A1 | HALO-SUBSTITUTED AMINO AZA-HETEROARYL COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2022-11-03 | — | — | WO | disclosed |
| CN-113923988-A | Substituted arylmethyl and heteroarylmethyl ureas, analogs thereof, and methods of using the same | 爱彼特生物制药公司 | 2022-01-11 | — | — | CN | disclosed |
| EP-3893645-A1 | SUBSTITUTED ARYLMETHYLUREAS AND HETEROARYLMETHYLUREAS, ANALOGUES THEREOF, AND METHODS USING SAME | Arbutus Biopharma Corporation (CA) | 2021-10-20 | — | — | EP | disclosed |
| WO-2020123674-A1 | SUBSTITUTED ARYLMETHYLUREAS AND HETEROARYLMETHYLUREAS, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2020-06-18 | — | — | WO | disclosed |
| EP-3299368-B1 | NOVEL AMINO PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2020-02-26 | — | — | EP | disclosed |
| EP-3074386-B1 | NOVEL AMINO PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2017-10-11 | — | — | EP | disclosed |
| US-20040122223-A1 | Non-natural nucleotides and dinucleotides | CELLTECH R & D LIMITED (GB) | 2004-06-24 | — | — | US | disclosed |
| EP-1368366-A1 | NON-NATURAL NUCLEOTIDES AND DINUCLEOTIDES | Celltech R & D Limited (GB) | 2003-12-10 | — | — | EP | disclosed |
| WO-2002062816-A1 | NON-NATURAL NUCLEOTIDES AND DINUCLEOTIDES | CELLTECH R & D LIMITED (GB) | 2002-08-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122223-A1 | Non-natural nucleotides and dinucleotides | P2RY1, P2RY11, P2RY13 | JAK2 4329/4885RPS6KA3 3062/4885MELK 2983/4885 |
| US-20230045421-A1 | SUBSTITUTED ARYLMETHYLUREAS AND HETEROARYLMETHYLUREAS, ANALOGUES THEREOF, AND METHODS USING SAME | HAVCR2, HMBS, AHCY | JAK2 1422/4885RPS6KA3 4201/4885MELK 1389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.